Fig. 4

SARS-CoV-2 vaccination for CAR-T recipients. For individuals without infection, the initial vaccination series should be completed at least 2 weeks prior to beginning lymphodepleting conditioning. Regardless of infection or vaccination history, patients are advised to receive primary and booster vaccines after CAR-T treatment. If patients are infected with SARS-CoV-2 post CAR T-cell infusion, revaccination should be carried out 6 months after recovery from COVID-19. LD: Lymphodepleting conditioning